Formal opening of “Science Campus Braunschweig-Süd”
Life science campus with a focus on translation
On October 6, 2017, the “Science Campus Braunschweig-Süd” was formally opened by Lower Saxony Minister of Science and Culture Gabriele Heinen-Kljajić and Braunschweig’s Oberbürgermeister (Lord Mayor) Ulrich Markurth.
The opening ceremony with guests from academia, industry and government is a highlight during Braunschweig’s anniversary year “10 years City of Science” and an important milestone in the ongoing development of the Braunschweig Region of Science. Fraunhofer ITEM with its Division of Pharmaceutical Biotechnology is one of the campus partners, as well as Helmholtz Center for Infection Research (HZI), German Center for Infection Research (DZIF), Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, Technische Universität Braunschweig, and Biotechnological School Lab Braunschweig (BioS). The aims of the new umbrella brand name “Science Campus Braunschweig-Süd” shared by these institutions are to enhance visibility of this state-of-the-art life science campus both at the regional and national levels, promote networking between the partners, and attract new cooperation partners and talented young people. In addition, with the support of the municipal government of Braunschweig, it has been possible to implement a new signage concept in the public arena.
Fraunhofer ITEM with its Hannover and Braunschweig sites closely collaborates with the other partners on the Science Campus. “Here in Braunschweig, ideas are translated into innovative processes for novel biopharmaceuticals that are eventually administered to patients as investigational medicinal products,” says Prof. Norbert Krug, Fraunhofer ITEM Executive Director. The institute has thus closed the gap between preclinical and clinical drug development. It is the only institution in Germany’s publicly funded research landscape that is able to both develop manufacturing processes for new biopharmaceuticals and advance their development to the stage of first-in-man trials – thereby making an important contribution to medical translational research.